SCHEMBL5212059

SCHEMBL5212059

Cc1ccc(S(=O)(=O)OC#N)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 3/20 0.48
ALDH1A1 P00352 4/20 0.47
MAPT P10636 2/20 0.47
TDP1 Q9NUW8 2/20 0.47
CYP1A2 P05177 2/20 0.47
CYP3A4 P08684 2/20 0.47
CYP2C9 P11712 2/20 0.47
CYP2C19 P33261 2/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
NPC1 O15118 1/20 0.47
NFKB1 P19838 1/20 0.47
S100A4 P26447 1/20 0.47
MTOR P42345 1/20 0.47
RAB9A P51151 1/20 0.47
NFKB2 Q00653 1/20 0.47
RELA Q04206 1/20 0.47
TP53 P04637 1/20 0.47
CYP2D6 P10635 1/20 0.47
HPGD P15428 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17429321 0.79 MEN1 (0.43) ALDH1A1MEN1KMT2ACA1CA2
SCHEMBL9341811 0.79 GAA (0.48) GAAALDH1A1MAPTTDP1CYP1A2
SCHEMBL17429314 0.78 HTR6 (0.44) ALDH1A1MAPTTDP1KMT2AHPGD
Water SCHEMBL3352692 0.78 GAA (0.56) GAAALDH1A1MAPTTDP1CYP1A2
SCHEMBL5332415 0.78 GAA (0.46) GAAALDH1A1MAPTTDP1CYP1A2
Acetonitrile SCHEMBL28199329 0.78 GAA (0.46) GAAALDH1A1MAPTTDP1CYP1A2
SCHEMBL17429307 0.76 KIF11 (0.47) MAPTKMT2ACA1CA2CA12
SCHEMBL27331250 0.76 PARL (0.49) GAAALDH1A1CA1CA2CA12
Water SCHEMBL8799285 0.76 GAA (0.54) GAAALDH1A1MAPTTDP1CYP1A2
SCHEMBL8482569 0.76 GAA (0.54) GAAALDH1A1MAPTTDP1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3990924-A1 DETECTION OF PATHOGENIC BACTERIA BY CHEMICALLY FUNCTIONALIZED CELLULOSE Centre national de la recherche scientifique (FR) 2022-05-04 EP disclosed
WO-2021233783-A1 PROCESS OF PREPARING BUTYL-(5S)-5-({2-[4-(BUTOXYCARBONYL)PHENYL]ETHYL}[2-(2-{[3-CHLORO-4'-(TRIFLUOROMETHYL)[BIPHENYL]-4-YL]METHOXY}PHENYL)ETHYL]AMINO)-5,6,7,8-TETRAHYDROQUINOLINE-2-CARBOXYLATE BAYER AKTIENGESELLSCHAFT (DE) 2021-11-25 WO disclosed
US-20210300921-A1 EP4 INHIBITORS AND SYNTHESIS THEREOF ASKAT INC. (JP) 2021-09-30 US disclosed
US-9947965-B2 Nonaqueous electrolyte solution and nonaqueous electrolyte battery using same MITSUBISHI CHEMICAL CORPORATION (JP) 2018-04-17 US disclosed
US-20160013517-A1 NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE BATTERY USING SAME MITSUBISHI CHEMICAL CORPORATION (JP) 2016-01-14 US disclosed
US-9217222-B2 Prevention of body odour HENKEL AG & CO. KGAA (DE) 2015-12-22 US disclosed
US-20150364794-A1 NONAQUEOUS ELECTROLYTE SOLUTION AND NONAQUEOUS ELECTROLYTE BATTERY USING SAME MITSUBISHI CHEMICAL CORPORATION (JP) 2015-12-17 US disclosed
CN-102124064-B Composition for forming silicon-containing resist underlayer film with onium group NISSAN CHEMICAL IND LTD 2014-09-03 CN disclosed
CN-101296907-B Diaminopyrimidines as P2X3 and P2X2/3 modulators HOFFMANN LA ROCHE 2013-03-27 CN disclosed
US-20120164097-A1 PREVENTION OF BODY ODOUR HENKEL AG & CO. KGAA (DE) 2012-06-28 US disclosed
CN-102124064-A Composition for forming silicon-containing resist underlayer film with onium group NISSAN CHEMICAL IND LTD 2011-07-13 CN disclosed
CN-101296907-A Diaminopyrimidines as P2X3 and P2X2/3 modulators ROCHE PALO ALTO LLC (CH) 2008-10-29 CN disclosed
US-20070275954-A1 Novel Fused Heterocycles and Uses Thereof ASTRAZENECA AB (SE) 2007-11-29 US disclosed
CN-1956971-A Novel fused heterocycles and application thereof ASTRAZENECA AB (SE) 2007-05-02 CN disclosed
EP-1751119-A1 NOVEL FUSED HETEROCYCLES AND USES THEREOF AstraZeneca AB (SE) 2007-02-14 EP disclosed
WO-2005111001-A1 NOVEL FUSED HETEROCYCLES AND USES THEREOF ASTRAZENECA AB (SE) 2005-11-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210300921-A1 EP4 INHIBITORS AND SYNTHESIS THEREOF PTGER4, EPB41, CDK4 GAA 4866/4885ALDH1A1 2142/4885MAPT 4594/4885
US-20120164097-A1 PREVENTION OF BODY ODOUR CUTA, NOTUM, SLC14A1 GAA 2904/4885ALDH1A1 642/4885MAPT 440/4885
US-20070275954-A1 Novel Fused Heterocycles and Uses Thereof VIP, CCKBR, HRH2 GAA 1097/4885ALDH1A1 836/4885MAPT 4771/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.